ANGPTL4 & Adipose RNA Update

A modest week: a mechanistic paper shows DHA raises adipocyte Angptl4 via PPARγ to suppress LPL, a sarcopenia atlas casts adipose-derived ANGPTL4 as a paracrine brake on muscle regeneration, and a J Control Release review places adipose RNAi in Phase 1/2a among extrahepatic delivery platforms.

A new PNAS paper introduces an adipose-directed antisense oligonucleotide that preserves lean mass and boosts fat-selective weight loss alongside semaglutide, while a large Mendelian-randomization study adds human genetic support for ANGPTL4 inhibition as a kidney-protective strategy.

A thin week for ANGPTL4-specific news, but one strong hit on the delivery side — a microneedle/LNP-mRNA platform that directly targets subcutaneous adipose tissue to reverse fibrotic changes in skin disease.

A genuinely thin week — the 8-day PubMed window surfaced 14 candidates, but the four that were actually on-topic (two direct ANGPTL4-in-cancer mechanism papers, an adipokine/sleep review touching ANGPTL4, and an adipose-targeted circRNA-LNP weight-loss study) had all already been covered in prior cycles, and the remaining hits were off-topic (bovine genetics, wound-healing exosomes, autism modeling, Duchenne muscular dystrophy). No new on-topic papers this week.

A thin week for new science — one paper adds ANGPTL4 to the growing list of endometriosis biomarkers, and one describes an adipose-targeted lipid nanoparticle (not RNA-loaded, but relevant delivery-platform work) for reprogramming obese adipose tissue immunity.

It's a thin week on the core beat — every directly on-topic ANGPTL4 or adipose-RNA-delivery paper indexed in the past 8 days had already been covered in a prior episode, so this issue instead surfaces two adjacent adipose tissue macrophage papers relevant to metabolic complications and RNAi-based therapeutic strategies.

A thin week for new ANGPTL4-specific literature, but one strong hit on the RNA-delivery-to-metabolic-tissue side: a circular RNA/LNP formulation delivering GDF15 shows sustained weight loss and adipose thermogenic activation in obese mice.

A quiet week — the PubMed search returned 12 hits in the last 8 days, but 10 of the 12 had already been covered in prior episodes and the remaining 2 are off-topic, so there is no new ANGPTL4 or adipose-RNA-delivery research to report this cycle.

The week's strongest signal is a Molecular Therapy paper using antibody-targeted lipid-coated nanoparticles to deliver siRNA into a specific pathogenic adipose stromal cell population — a concrete adipose-RNA-delivery advance — alongside a cluster of new mechanistic data tying ANGPTL4 to cancer metastasis, immune evasion, and renal fibrosis, plus a registered systematic-review protocol on ANGPTL3/ANGPTL4/APOC3 inhibitors for hypertriglyceridemia-driven pancreatitis.

A thin week for ANGPTL4-specific literature — every ANGPTL4 hit in the 8-day PubMed window duplicated prior coverage — but three adjacent papers are worth a look: two on adipocyte differentiation mechanisms and one on an siRNA nanovesicle delivery platform.

The strongest new finding this week ties ANGPTL4 directly to podocyte lysosomal dysfunction in diabetic kidney disease, while a second paper reinforces ANGPTL4's role in tumor immune evasion — together they widen the therapeutic rationale for ANGPTL4 inhibition beyond lipid metabolism; no new adipose-tropic RNA delivery platform papers surfaced this week.

A quiet week for the core beat — no new adipose-targeted RNA delivery papers and no new patents, but two ANGPTL4 biology papers stand out: a new placental biomarker study in gestational diabetes and a review reaffirming ANGPTL4's place in the causal triglyceride-ASCVD pathway.

No new adipose-targeted RNA delivery papers turned up this week, but three fresh papers deepen the case for ANGPTL4 as a disease-driving signal outside classic lipid metabolism — in sleep-linked metabolic risk, cholangiocarcinoma metastasis, and colorectal cancer's tumor microenvironment.

A new review makes the clinical case for ANGPTL-axis therapeutics in dyslipidemia, while two mechanism papers add fresh evidence that ANGPTL4 drives drug resistance and inflammation in solid tumors — no adipose-targeted RNA delivery papers surfaced this cycle.

Three new mechanistic papers this week converge on ANGPTL4 as a secreted signal that drives fibrosis and immune evasion outside its classic lipid-metabolism role — in kidney, liver tumor stroma, and now the blood-brain barrier — while no new adipose-targeted RNA-delivery papers or patents cleared the bar.

A thin but focused week — ANGPTL4 surfaces in a gut-microbiome/adipose crosstalk review and in a mechanistic study linking YAP condensates to proangiogenic ANGPTL4 expression, while an adipocyte cell-death study employs adipocyte-specific siRNA to implicate caspase-8 in adipogenesis.

A thin week for direct ANGPTL4 therapeutics, but a standout paper demonstrates that circular RNA delivered via lipid nanoparticles can drive sustained GDF15-mediated fat burning in obese mice — a proof-of-concept for RNA-LNP therapies targeting adipose metabolism.

A thin week on the primary beat — two correspondence letters debate ANGPTL4 as a stroke biomarker, while two independent studies use siRNA knockdown in human and porcine adipose-derived stem cells to probe fat biology, reinforcing the utility of RNA tools in adipose tissue.

ANGPTL4 emerges prominently as a therapeutic target in a landmark Circulation Research review of triglyceride-rich lipoprotein metabolism and cardiovascular risk in diabetes, while new work in adipocyte biology highlights PPARγ-mediated transcriptional programs and antiadipogenic peptide mechanisms with direct ANGPTL4 relevance.

Three new papers this week illuminate ANGPTL4's role in tumor microenvironments, adipose-driven metabolic dysfunction in heart failure, and as an early-life obesity biomarker; no new adipose RNA delivery papers appeared in the lookback window.